Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11912-021-01128-5.pdf
Reference56 articles.
1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:24–32. https://doi.org/10.1093/annonc/mdt333.
2. Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):93–109. https://doi.org/10.1016/j.hoc.2011.10.004.
3. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol. 2002;55(6):348–59.
4. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-angiogenesis therapy in ovarian cancer: which patient is it most likely to benefit? Oncol Williston Park N. 2019;33(7):629378.
5. Decio A, Taraboletti G, Patton V, et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184(4):1050–61. https://doi.org/10.1016/j.ajpath.2013.12.030.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MMP-3 gene regulates the carcinogenesis and metabolic process of ovarian cancer, evidence from a Chinese population: Observational study and meta-analysis;Medicine;2023-12-15
2. PTPN13 Participates in the Regulation of Epithelial–Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells;International Journal of Molecular Sciences;2023-10-21
3. Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer;Cancers;2023-09-28
4. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer;Journal of Ovarian Research;2023-07-17
5. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial;Journal of Experimental & Clinical Cancer Research;2023-04-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3